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Abstract
Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated
remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic basal cell carcinoma,
however, has largely gone untested. Because PD-Ligand-1 (PD-L1) expression in other tumor types has been associated
with response to anti-PD-1, we investigated the expression of PD-L1 and its association with PD-1 expression in the basal
cell carcinoma tumor microenvironment. Among 40 basal cell carcinoma specimens, 9/40 (22%) demonstrated PD-L1
expression on tumor cells, and 33/40 (82%) demonstrated PD-L1 expression on tumor-infiltrating lymphocytes and
associated macrophages. PD-L1 was observed in close geographic association to PD-1+ tumor infiltrating lymphocytes.
Additionally, we present, here, the first report of an objective anti-tumor response to pembrolizumab (anti-PD-1) in a
patient with metastatic PD-L1 (+) basal cell carcinoma, whose disease had previously progressed through hedgehog
pathway-directed therapy. The patient remains in a partial response 14 months after initiation of therapy. Taken together,
our findings provide a rationale for testing anti-PD-1 therapy in patients with advanced basal cell carcinoma, either as
initial treatment or after acquired resistance to hedgehog pathway inhibition.
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Background
Basal cell carcinoma (BCC) is the most common human
cancer, though most tumors are eradicated using locally-
directed therapies [1]. In the small minority of patients
that develop surgically unresectable locally-advanced or
metastatic disease, currently available systemic therapies,
such as agents that curtail aberrant signaling along the
hedgehog (Hh) pathway, are frequently ineffective in
bringing about durable anti-tumor responses [2–6].
Over the past several years, monoclonal antibodies that
block immune checkpoint proteins (e.g., anti-programmed
death-1 (PD-1), PD-Ligand-1 (PD-L1)), have demonstrated
remarkable efficacy in controlling the growth of multiple
tumor types [7]. In several studies, the expression of PD-L1
– a major ligand of PD-1 – in the tumor microenvironment
has been associated with an increased likelihood of an anti-
tumor response to anti-PD-1. BCC, however, has largely
gone untested and little is known about the expression of
immunoregulatory molecules in the BCC microenviron-
ment or about the capacity of PD-1-pathway-directed ther-
apies to trigger an effective anti-tumor response [8–10].
In the current study, we characterized PD-L1 and PD-
1 expression patterns in the tumor microenvironment of
40 archived BCC specimens. Additionally, we studied a
pre-treatment tumor specimen and clinical and radio-
graphic response characteristics from one patient who
experienced a durable, objective anti-tumor response to
pembrolizumab (anti-PD-1) monotherapy.
Materials and methods
Following Institutional Review Board approval, 40 surgical
pathology specimens from 40 unique patients with BCC
were identified from the Johns Hopkins Hospital surgical
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pathology archives. Slides were reviewed by a board-
certified dermatopathologist (JMT) to confirm the diagno-
sis, and one representative paraffin block was chosen for
PD-L1 and PD-1 immunohistochemistry (IHC). PD-L1
expression was assessed using the murine anti-human
PD-L1 monoclonal antibody 5H1 (from Lieping Chen,
Yale University, New Haven, CT) at a concentration of
0.1 μg/mL, as previously described [11]. PD-L1 expression
on tumor cells and immune cells were scored separately.
Cases demonstrating at least 5% membranous (cell
surface) expression of PD-L1 were considered positive.
Immunohistochemistry for PD-1 was performed using a
primary mouse anti-human mAb (clone Nat105, at
1:1000), following an antigen retrieval of 10 min in citrate
buffer, pH 6.0 at 120 C. A secondary anti-mouse IgG1
antibody was used at 1.0 μg/ml. Amplification was
performed by using Perkin Elmer biotin TSA, Dako strep-
tavidin HRP and then visualized by DAB staining. The
geographic association between PD-L1 and PD-1 expres-
sion in the tumor microenvironment was also assessed.
For the specimen from the patient demonstrating a
response to anti-PD-1, an extended panel of IHC markers
(CD4, CD8, TIA-1 and CD68) was performed according
to standard automated methods.
Results
Forty specimens from 40 unique patients were evalu-
able. All were primary lesions that were locally ag-
gressive or recurrent. The tumors ranged in size from
2 to15 cm in greatest dimension. Nine of forty (22%)
demonstrated PD-L1 expression on tumor cells, and
33/40 (82%) demonstrated PD-L1 expression on
tumor-infiltrating lymphocytes (TIL) and associated
macrophages. All (40/40, 100%) of cases had varying
degrees of either true TIL present or lymphocytes
present in the immediate extratumoral stroma. PD-1
expression was seen on lymphocytes in the tumor
microenvironment of each case, including the 16/40
(40%) cases that had only rare lymphocytes present.
All (33/33) cases with PD-L1 expression on tumor or
macrophages showed an association with PD-1+ TIL
(Fig. 1). There were no cases that demonstrated con-
stitutive PD-L1 expression, independent of TIL [11].
Case presentation
A 67-year-old woman presented in 2007 with a large
BCC of the skin of the right posterior neck. She
underwent wide local excision followed by adjuvant
electron radiotherapy. In 2011 she developed a surgi-
cally unresectable recurrence and began therapy on a
phase 1 clinical trial of the Hh pathway inhibitor sari-
degib (IPI-926; clinicaltrials.gov ID# NCT00761696).
Although radiographically her best overall response
per RECIST criteria was stable disease, clinically, her
symptoms related to tumor growth improved dramat-
ically for several months, then worsened about
12 months after having initiated therapy.
She then pursued treatment on a phase 1 clinical trial
of AZD6244 (MEK inhibitor) and IMC-A12 (a fully
human IgG1 monoclonal antibody directed against
insulin-like growth factor-1 receptor (IGF-1R); clinical-
trials.gov ID# NCT01061749). Her disease progressed
within 6 months, requiring palliative radiotherapy.
In late 2014 her neck pain increased and CT scans dem-
onstrated multiple lung metastases. Re-initiation of Hh in-
hibition was considered but, based on previous clinical
experience, the likelihood of anti-tumor activity was felt to
be low [12]. The patient preferred to avoid the toxicity
associated with standard cytotoxic chemotherapy.
Although we had not yet assessed PD-L1 expression
in this patient’s tumor, support for the use of PD-1
pathway-directed therapy came from pre-clinical stud-
ies demonstrating that BCC typically caries a high
genetic mutation burden, a characteristic associated
with response to PD-1 blockade in other tumor types
[13, 14]. Additionally, BCCs undergoing spontaneous
regression (presumably immune-mediated) contain
elevated levels of T-helper type-1 (Th1) cytokines
(e.g., interferon gamma) and infiltrating activated T
cells [15, 16].
Pembrolizumab (anti-PD-1) was administered at
2 mg/kg IV every 3 weeks beginning in December
2015. The following month, the patient reported that
her pain medication requirement had decreased sub-
stantially. CT scans performed 4 months into therapy
demonstrated a partial response (PR) to therapy per
RECIST 1.1 criteria (Fig. 2). Fourteen months into
therapy, a PR is ongoing. The patient has experi-
enced subclinical hypothyroidism, possibly drug-
related.
Immunohistochemical evaluation of the patient’s pre-
treatment BCC demonstrated PD-L1 expression on im-
mune cells but not tumor cells (Fig. 3). This immune
infiltrate was composed of a mixture of CD4 and CD8+
T cells as well as CD68+ macrophages. Approximately
50% of the lymphocytes present expressed PD-1. Immu-
nohistochemical stains for HLA-I and II were not
performed, as they are not yet fully validated in our
laboratories.
Discussion
The biology of BCC presents opportunities for both
immune-mediated tumor regression and escape from
immune surveillance. Factors that may increase BCC’s
immunogenicity include its high rate of cancer-testis
antigen expression [17], copious numbers of tumor-
infiltrating CD8+ T cells [18], and a genetic mutational
burden which is among the highest reported in any
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human cancer type [14, 19–21]. Indeed, many of the
cancers against which immune checkpoint therapy is
effective (e.g., melanoma, non-virus-associated Merkel
cell carcinoma and microsatellite unstable neoplasms)
harbor large genetic mutational loads [22, 23]. A re-
cent case report from Ikeda and colleagues describes a
near-complete response to nivolumab (anti-PD-1) in a
patient with metastatic BCC whose tumor carried a
particularly high mutational burden (450 mutations
per megabase) [9]. Conversely, BCCs demonstrate low
levels of MHC-I expression [24] and contain abundant
regulatory T cells in the tumor microenvironment [18],
both of which may suppress anti-tumor immunity and
allow for immune escape.
The administration of various anti-neoplastic therapies
may alter the immunological profile in BCCs. For example,
application of imiquimod to BCC results in upregulation of
MHC-I expression [17]. Likewise, administration of the Hh
pathway inhibitors vismodegib or sonidegib to patients with
BCC triggers increases in tumor-infiltrating T cells and
tumor cell MHC-I expression [25]. Despite these seemingly
beneficial immunological effects, Hh pathway inhibitors
have demonstrated sub-optimal objective response rates of
15–60%, with median durations of response often
<12 months [3, 4, 6, 26].
Taken together, these findings suggest that appropriately-
activated immune responses directed against BCC may
control tumor growth. In the current study, we present a
pre-clinical rationale for, and clinical evidence of, potential
long-term anti-tumor immunity after administration of
anti-PD-1, an immune checkpoint blocker. Agents target-
ing immune checkpoints represent “common denominator”
therapies which can bring about durable anti-tumor
responses in patients with multiple tumor types [27].
PD-L1 expression on tumor cells and immune cells
has been shown to enrich for response to anti-PD-1/
L1 in various solid malignancies [7]. Here, we demon-
strate prominent expression of two of the checkpoint
pathway’s component molecules, PD-1 and PD-L1, in
BCC. Moreover, the cases in the current series exhibit
PD-1 and PD-L1 expression in close geographic prox-
imity to each other, a pattern consistent with adaptive
(i.e., interferon-gamma-mediated) immune resistance
[11]. The adaptive pattern of PD-L1 expression in the
tumor microenvironment can be further accentuated
by amplification of the 9p24.1 locus, which contains
PD-L1, −L2 and JAK2, the latter of which is an
interferon-gamma-responsive element. This alteration
was first described in Hodgkin lymphoma [28], then
recently illustrated in a case report of a patient with
BCC whose tumors regressed after administration of
anti-PD-1 [9]. Importantly, mutational burden and
PD-1/PD-L1 expression in the tumor microenviron-
ment do not appear to be directly linked [29]. Thus,
the current report highlights a novel biomarker sug-
gesting potential efficacy of anti-PD-1 in patients with
advanced BCC.
Fig. 2 Partial response of metastatic basal cell carcinoma to
pembrolizumab (anti-PD-1). Computed tomography (CT) scans
performed pre-therapy (top row) and 6.5 months after initiating
pembrolizumab (anti-PD-1, bottom row) demonstrate regression of
basal cell carcinoma lung metastases. Yellow arrowheads indicate sites
of metastases
Fig. 1 Geographic co-localization of PD-L1+ tumor cells and associated immune cells with PD-1+ infiltrating immune cells in BCC. PD-1, programmed
death-1; PD-L1, programmed death ligand-1. 200× original magnification, all panels
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Of note, the immune marker panel used in our study
was intended to support the aim of our investigation: to
explore expression of molecules comprising the PD-L1
axis in BCC as a rationale for clinical application of anti-
PD-1/PD-L1 agents. Development of an optimized
multiplex biomarker panel for BCC will likely include
assessment of additional immunoregulatory elements
(e.g., HLA-I and -II expression status), and will require a
large cohort of patients.
In conclusion, our laboratory and clinical findings sug-
gest that PD-1 blockade should be considered as salvage
therapy in patients with advanced BCC whose disease
has progressed after standard Hh pathway inhibition.
Our results also provide a rationale for ongoing clinical
trials of PD-1 pathway blockade agents in patients with
advanced BCC, either as first-line therapy or in combin-
ation with or after treatment with Hh inhibitors (e.g.,
NCT02690948).
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Fig. 3 Immune elements in the microenvironment of a pre-treatment basal cell carcinoma from a patient who responded to anti-PD-1 therapy.
The immune infiltrate abuts the tumor islands and is composed of a mixture of CD4 and CD8+ T-cells at a ratio of approximately 2:1. The CD8 cells are
cytotoxic, as supported by the punctate cytoplasmic TIA-1 immunostaining. The lymphocytic infiltrate is accompanied by CD68+ macrophages. PD-1 is
seen on approximately half of the lymphocytes present, and is immediately adjacent to PD-L1 expression in the tumor microenvironment, consistent
with an immune microenvironment primed for potential response to PD-1/PD-L1 checkpoint blockade. PD-L1 is expressed predominantly on immune
cells, rather than tumor cells in this example. H & E, hematoxylin and eosin, PD-(L)1, programmed death-(Ligand)1. 200× original magnification, all panels
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